At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Life Sciences

Therapeutics

Lykos Therapeutics (formerly MAPS PBC)

Michael Mullette

Dr. Berra Yazar-Klosinski

Andrew Septimus

Kacy Hutchison

Michelle Lacy

William Stewart

Blair Clark - Schoeb

Joy Sun Cooper

Berra Yazar - Klosinski

Allison Rosenthal

The Leadership Team at Lykos Therapeutics is responsible for guiding the company's strategic direction and ensuring alignment with its mission to innovate in mental health treatment. Comprising key executives from diverse fields—including scientific research, therapy training, commercial operations, and public advocacy—the team collaborates to oversee the development and commercialization of novel therapies while prioritizing public benefit in all decision-making processes. Their collective expertise drives the company's commitment to rigorous scientific standards and ethical practices in addressing mental health challenges.

Leadership Team

Clinical Research and Development

Financial and Administrative Support

Leadership Team

About

Team members

Other teams at Lykos Therapeutics (formerly MAPS PBC)

Clinical Research and Development

Financial and Administrative Support